Loading
Emapalumab switches off interferon gamma, the signal behind the runaway immune activation of haemophagocytic lymphohistiocytosis (HLH), a condition that can also be triggered by lymphoma and by CAR-T therapy.
Emapalumab is a monoclonal antibody against interferon gamma, approved in the United States in 2018 for primary haemophagocytic lymphohistiocytosis (HLH) that is refractory, recurrent or progressive, or where conventional HLH therapy is not tolerated; the label was later extended to HLH and macrophage activation syndrome in Still's disease. HLH matters in oncology because lymphomas and CAR-T cell therapy can set it off, and treatment protocols borrow the etoposide and dexamethasone used for the primary form. Use of emapalumab in these secondary, cancer-linked forms is off label and reported in case series rather than trials.
Binds free and receptor-bound interferon gamma and neutralises it, damping the macrophage and T-cell activation loop that drives haemophagocytic lymphohistiocytosis.
1.Emapalumab binds its target.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
| Region | Year | Indication |
|---|---|---|
| US | 2018 | Primary haemophagocytic lymphohistiocytosis, refractory, recurrent or progressive, or intolerant of conventional therapy |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Emapalumab" OR ABSTRACT:"Emapalumab" OR TITLE:"Gamifant" OR ABSTRACT:"Gamifant" OR TITLE:"Emapalumab-lzsg" OR ABSTRACT:"Emapalumab-lzsg" OR TITLE:"NI-0501" OR ABSTRACT:"NI-0501") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Emapalumab, not a curated reading list.
Shares Diffuse large B-cell lymphoma and the tag supportive-care.
Shares Diffuse large B-cell lymphoma and the tag supportive-care.
Shares Diffuse large B-cell lymphoma and the tag supportive-care.
Shares Diffuse large B-cell lymphoma and the tag supportive-care.
Shares Sobi (Swedish Orphan Biovitrum), Diffuse large B-cell lymphoma.
Shares Cytokine release syndrome (CRS), CAR-T cell therapy, Diffuse large B-cell lymphoma.
Shares Sobi (Swedish Orphan Biovitrum), Diffuse large B-cell lymphoma.